Kalaris Therapeutics
KLRS
30 hedge funds and large institutions have $35.7M invested in Kalaris Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
2.75% less ownership
Funds ownership: 74.19% → 71.45% (-2.7%)
6% less funds holding
Funds holding: 32 → 30 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
68% less capital invested
Capital invested by funds: $111M → $35.7M (-$75.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$350K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$233K |
| 3 |
Squarepoint
New York
|
+$201K |
| 4 |
Millennium Management
New York
|
+$169K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
Gilead Sciences
Foster City,
California
|
-$1.83M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.62M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$546K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$173K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $134 | -$1.11K | -245 | -83% |
|
|
PA
27
Parallel Advisors
San Francisco,
California
| $131 | – | – | – |
|
|
FFA
28
Farther Finance Advisors
San Francisco,
California
| $88 | – | – | – |
|
|
SS
29
SBI Securities
Tokyo,
Japan
| $27 | +$45 | +10 | New |
|
|
EC
30
EcoR1 Capital
San Francisco,
California
| – | -$1.62M | -201,718 | Closed |
|
|
WP
31
Woodline Partners
San Francisco,
California
| – | -$173K | -21,519 | Closed |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$111K | -13,796 | Closed |
|
|
CCM
33
Coldstream Capital Management
Bellevue,
Washington
| – | -$1.67K | -208 | Closed |
|
|
EWA
34
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$241 | -30 | Closed |
|
35
Barclays
London,
United Kingdom
| – | -$8 | -1 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$384 | +85 | New |
|
KLRS Hedge Fund Activity: Q2 2025 in Review
30 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q2 2025, worth a combined $35.7M — down 68% from $111M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KLRS and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $350K. The largest seller was Gilead Sciences, cutting an estimated $1.83M.
- 30 institutional investors held Kalaris Therapeutics (KLRS) as of Q2 2025, down from 32 in Q1 2025.
- Funds reported $35.7M of Kalaris Therapeutics stock for Q2 2025, down 68% quarter-over-quarter.
- 4 funds opened new Kalaris Therapeutics positions in Q2 2025 and 6 closed out, a net change of -2 holders.
- The largest Kalaris Therapeutics buyer in Q2 2025 was Renaissance Technologies, an estimated $350K added.
- The largest Kalaris Therapeutics seller in Q2 2025 was Gilead Sciences, an estimated $1.83M sold.
Based on aggregated 13F filings for Q2 2025.